InSphero

InSphero, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.

InSphero announced its distribution partnership with Chayon. This partnership will bring InSphero’s reliable and scalable 3D in vitro solutions for drug development to South Korean researchers.

InSphero AG is pleased to announce its exclusive commercialization partnership with Genome Biologics, based in Frankfurt, Germany.

InSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of in vitro models in MASH Drug Discovery.

The industry's search for alternatives to traditional preclinical drug testing methods has led to a growing interest in the potential of three-dimensional (3D) in vitro models. To delve deeper into this subject, Technology Networks spoke with Madhu Lal-Nag, chief scientific officer at InSphero, a 3D in vitro model company with a mission to “modernize drug discovery in ways that inspire researchers everywhere to reach their full potential and fuel a new era of breakthrough therapies.”